Sign in
Taking people in NetherlandsPhase 4

Studies how pneumococcal vaccines act in lymph nodes across ages and HIV

Compares lymph node immune response to pneumococcal vaccines in younger, older and HIV-positive adults.

Key facts

Who runs it
Academisch Ziekenhuis Leiden
Where
Leiden, NetherlandsSee the site
Registry title
The impact of vaccine platform, age and HIV infection on germinal centre formation.
Status
Recruiting
Phase
Phase 4
People taking part
75 people, planned
Started
6 Mar 2025
Expected to end
1 Dec 2026
Type of study
Interventional
Record updated
31 January 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for generally healthy adults aged 20-40 or over 60, and adults aged 20-40 living with HIV whose virus is controlled by treatment.

Age
20 - 40 years, or over 60 years (HIV group: 20 - 40 years)
Sex
Men and women can join.
Disease stage
HIV group: documented HIV infection with the virus under control (HIV copies < 200/ml).
Earlier treatment
HIV group: must be on active anti-retroviral therapy. No earlier pneumococcal vaccination and no earlier pneumococcal infection.
Biomarker or test result
HIV group: HIV copies < 200/ml.

Main reasons for not taking part

  • Pregnancy at time of inclusion, or breastfeeding during the study
  • Use of immunosuppressive medication
  • Use of blood thinners such as DOACs or vitamin K antagonists
  • Known hypersensitivity to vaccine components
  • A primary immune disorder or primary coagulopathy

The registry criteria, word for word

Show all 18 criteriaShow less

Who can take part

  • Age between 20 - 40 years or age > 60 years
  • Generally Healthy
  • For PLWH group: aged 20 - 40 years, with documented HIV infection on active anti-retroviral therapy resulting in viral supression ( HIV copies < 200/ml)

Who cannot take part

  • Use of immunosuppressive medication
  • Use of direct acting anticoagulant drugs (DOACs) or vitamin K antagonists
  • Recent (past month) surgery in axillar area or major surgery elsewhere
  • Chronic nasal corticosteroid use (> 3 months)
  • Vaccination < 1 month before inclusion
  • Prior documented pneumococcal vaccination
  • Prior pneumococcal infection
  • Known hypersensitivity to vaccine components
  • History of severe nose bleeds
  • Documented primary immune disorder or primary coagulopathy
  • Pregnancy at time of inclusion
  • Fever at time of inclusion
  • Inability to provide informed consent
  • Inability to visit the LUMC for study procedures
  • Breastfeeding during the course of the study

Where in Netherlands

  • Leids Universitair Medisch Centrum (LUMC)Leiden, NetherlandsTaking people

About the trial

What the trial wants to find out

The primary objective of the trial will be to compare germinal centre formation after pneumococcal vaccination between different populations (health young vs healthy older adults; healthy young vs people living with HIV) as well as between different vaccine platforms.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
Using lymph nOde fine needle aspiration to assess the effeCt of pnEumococcal vAcciNe platform, Age and HIV infection on Germinal cEntre formation (OCEAN-AGE)
Plain-language title
Studies how pneumococcal vaccines act in lymph nodes across ages and HIVGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
31 January 2025